Search

Ruth F Lupu

from Rochester, MN
Age ~69
Get Report
Also known as:
Ruth J Lupu, Lupu Ruth, Ruth Kupe
Phone and address:
2167 Hill Ave, Rochester, MN 55902
(507) 206-4744
Related to:
Mario A RiveraJackie RiveraSylvia Malave, 54Heather T Rivera, 45Maria Rivera, 79
Connected to:
Aurelia Lupu, 95Catalin Lupu, 56Chris F Lupu, 45Constantin C Lupu, 82Darrell W Lupu, 53Flavius Lupu, 50Ioana Lupu, 46Linda L Lupu, 44Loredana Lupu, 42Michael S Lupu, 54

Ruth Lupu Phones & Addresses

  • 2167 Hill Ave, Rochester, MN 55902 (507) 206-4744
  • 2881 Idlewood Ln, Highland Park, IL 60035 (847) 432-0412
  • 650 Teak Ct, Walnut Creek, CA 94598 (925) 930-6588
  • Gaithersburg, MD
  • Rockville, MD
  • Lane, IL
  • 2167 Hill Pl SW, Rochester, MN 55902

Work

Position: Service Occupations

Education

Degree: Bachelor's degree or higher

Resumes

Resumes

Ruth Lupu Photo 1

Professor, Medicine And Experimental Pathology

View page
Location:
Rochester, MN
Industry:
Health, Wellness And Fitness
Work:
Mayo Clinic
Professor, Medicine and Experimental Pathology
Northwestern University 2002 - Jun 2008
Professor
University of Berkeley California Feb 1996 - Jun 2002
Assosiate Professor
Georgetown University Jan 1989 - Jan 2002
Assistant Professor
Education:
Tel Aviv University
Skills:
Cell Biology
Biochemistry
Cell Culture
Genetics
Lifesciences
Cell
Clinical Research
Immunohistochemistry
Life Sciences
Ruth Lupu Photo 2

Ruth Lupu

View page

Publications

Us Patents

Materials And Methods For Treating And Preventing Her-2/Neu Overexpressing, Fas-Elevated Cancer Cells

View page
US Patent:
20070207975, Sep 6, 2007
Filed:
Jan 9, 2007
Appl. No.:
11/651803
Inventors:
Javier Menendez - Evanston IL, US
Ruth Lupu - Highland Park IL, US
Assignee:
EVANSTON NORTHWESTERN HEALTHCARE - Evanston IL
International Classification:
A61K 48/00
A61K 31/202
US Classification:
514044000, 514560000
Abstract:
The invention provides methods for treating cancer cells overexpressing Her-2/neu, the product of the erbB-2 gene, comprising administering a therapeutically effective amount of an unsaturated fatty acid. The cancer cells amenable to treatment exhibit relatively elevated activity levels of fatty acid synthase. Exemplary fatty acids useful in the methods of the invention include ω-9 monounsaturated fatty acids (e.g., oleic acid), ω-6 polyunsaturated fatty acids (e.g., γ-linolenic acid) and ω-3 polyunsaturated fatty acids (e.g., α-linolenic acid). The invention also provides methods of preventing cancer comprising administering a prophylactically effective amount of a fatty acid and kits for preventing and/or treating cancer comprising a fatty acid and a conventional anti-cancer therapeutic.

Ligand Growth Factor Gp30 That Binds To The Erbb-2 Receptor Protein And Induces Cellular Responses

View page
US Patent:
60402903, Mar 21, 2000
Filed:
Aug 26, 1996
Appl. No.:
8/703089
Inventors:
Marc E. Lippman - Bethesda MD
Ruth Lupu - Gaithersburg MD
Assignee:
Georgetown University - Washington DC
International Classification:
C07K 14475
C07K 1702
A61K 3818
US Classification:
514 12
Abstract:
The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays. The present invention also pertains to a method for inhibiting the growth of adenocarcinoma cells.

Ligand Growth Factors That Bind To The Erbb-2 Receptor Protein And Induce Cellular Responses

View page
US Patent:
55784828, Nov 26, 1996
Filed:
Jul 26, 1993
Appl. No.:
8/096277
Inventors:
Marc E. Lippman - Bethesda MD
Ruth Lupu - Gaithersburg MD
Assignee:
Georgetown University - Washington DC
International Classification:
C12N 138
C12N 526
US Classification:
4352401
Abstract:
The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays. A method for inhibiting the growth of adenocarcinoma cells in a human, which cells overexpress the oncogene erbB-2, which entails administering to said human an amount of a 30 kDa glycoprotein effective to inhibit the growth of said cells.

Binding Peptides Which Interact With Ligand Growth Factors Of The Epidermal Growth Factor Receptor And Erbb-2 Receptor

View page
US Patent:
58745289, Feb 23, 1999
Filed:
Oct 27, 1994
Appl. No.:
8/117187
Inventors:
Ruth Lupu - Gaithersburg MD
Marc E. Lippman - Bethesda MD
Assignee:
Georgetown University - Washington DC
International Classification:
C07K 752
C07K 700
US Classification:
530317
Abstract:
The present invention relates to blocking peptides which are capable of binding to ligands for the erbB-2 receptor or the epidermal growth factor receptor (EGFR). The blocking peptides of the invention are used to detect the presence of such ligand molecules. In addition, the blocking peptides are useful in inhibiting or preventing the growth of adenocarcinoma cells which express the erbB-2 receptor or the EGFR.

Antibodies To Ligand Growth Factors

View page
US Patent:
58696180, Feb 9, 1999
Filed:
Oct 31, 1995
Appl. No.:
8/550815
Inventors:
Marc E. Lippman - Bethesda MD
Ruth Lupu - Gaithersburg MD
International Classification:
C07K 1618
C07K 1622
C07K 1624
C07K 1626
US Classification:
5303871
Abstract:
The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays.

Using Fatty Acid Synthase Inhibitors To Treat Fibrosis

View page
US Patent:
20220313654, Oct 6, 2022
Filed:
Feb 16, 2022
Appl. No.:
17/673518
Inventors:
- Rochester MN, US
Ruth Lupu - Rochester MN, US
Mi-Yeon Jung - Rochester MN, US
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A61K 31/365
A61P 11/00
A61K 31/341
A61K 31/713
C12N 15/113
A61P 43/00
Abstract:
This document relates to materials and methods for treating fibrosis (e.g., pulmonary fibrosis). For example, this document provides methods for using one or more fatty acid synthase (FASN) inhibitors to treat a mammal having fibrosis (e.g., pulmonary fibrosis), and/or a complication associated with fibrosis (e.g., hypoxia caused by pulmonary fibrosis).

Using Fatty Acid Synthase Inhibitors To Treat Fibrosis

View page
US Patent:
20190070145, Mar 7, 2019
Filed:
Mar 22, 2017
Appl. No.:
16/086798
Inventors:
- Rochester MN, US
Ruth Lupu - Rochester MN, US
Mi-Yeon Jung - Rochester MN, US
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A61K 31/365
A61P 11/00
Abstract:
This document relates to materials and methods for treating fibrosis (e.g., pulmonary fibrosis). For example, this document provides methods for using one or more fatty acid synthase (FASN) inhibitors to treat a mammal having fibrosis (e.g., pulmonary fibrosis), and/or a complication associated with fibrosis (e.g., hypoxia caused by pulmonary fibrosis).
Control profile
Ruth F Lupu from Rochester, MN, age ~69 Get Report